新型生物标志物MDW HMGB1及OSM在脓毒症中的应用价值  

The value of novel biomarkers MDW HMGB1 and OSM in sepsis

作　　者：王敏[1] 马辰东 陈颐华 李增亮 张利鹏[1] Wang Min;Ma Chendong;Cheng Yihua;Li Zengliang;Zhang Lipeng(Department of Critical Care Medicine,the Affiliated Hospital of Inner Mongolia Medical University,Hohhot 010000,China)

机构地区：[1]内蒙古医科大学附属医院重症医学科,内蒙古呼和浩特010000

出　　处：《中国急救医学》2023年第12期1004-1008,共5页Chinese Journal of Critical Care Medicine

基　　金：内蒙古自治区重点研发和成果转化项目(2022YFSH0038);内蒙古医科大学附属医院博士启动项目(NYFYBS202105)。

摘　　要：虽然脓毒症在诊断和治疗方面有所改进,但重症监护病房(ICU)住院患者的发病率和病死率仍然很高。临床尚不能完全做到及早发现脓毒症,但对于已确诊的脓毒症患者,就应及早干预脓毒症进展,降低其病死率。因此,目前需要及早识别、较好预测脓毒症结局的生物标志物,以帮助临床医生解决其实际问题。近年来脓毒症相关生物标志物的研究广受外界关注,现重点对脓毒症早期诊断、风险预测相关标志物单核细胞分布宽度(MDW)、高迁移率族蛋白B1(HMGB1)及抑癌蛋白M(OSM)的最新研究进展做一综述。Despite improvements in the diagnosis and treatment of sepsis,the morbidity and the mortality of the patients in ICU remain unacceptable.Early clinical detection of sepsis is not yet fully achievable,and all we can do for the patients diagnosed with sepsis is to intervene in the continued progression of sepsis and reduce overall mortality.Therefore,we still need early identification of biomarkers that better predict sepsis outcome to help clinicians solve practical problems.In recent years,sepsis-related biomarkers have received wide attention.We now focus on a review of the latest research progress of monocyte distribution width(MDW),high mobility group box-1 protein(HMGB1),and oncostatin M(OSM)markers related to early diagnosis and prognosis of sepsis.

关 键 词：脓毒症 生物标志物 单核细胞分布宽度(MDW) 高迁移率族蛋白B1(HMGB1) 抑癌蛋白M(OSM) 

分 类 号：R459.7[医药卫生—急诊医学]